Allegro Ophthalmics: Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the 19th EURETINA Congress and The Retina Society 2019 Annual Meeting
Results of Allegro's Ex-U.S. Proof-of-Concept Trial with Integrin Regulator ALG-1007 for Dry Eye Disease Will Be Presented at the 37th Congress of the ESCRS Allegro Ophthalmics, LLC, a privately h...
Read full article »
Allegro is an ophthalmic biopharmaceutical company that develops integrin inhibition therapies for the treatment of ocular diseases.
Read more